Numerous studies have consistently reported large magnitudes of benefits in all the disease’s phases but with the most significant public health impact in the prevention of transmission. On this compelling evidence, we recommend Ivermectin’s administration for both prophylaxis in all high-risk patients as well as in the early and late phases of the disease. If this were to occur nationally, we predict that, like in many of the regions shown above, the pandemic will end, the economy can re-open, social interactions and activity can resume, and life can normalize. The expected impact will allow our nation to grow and focus on the multitude of other pressing problems facing our society.
| exec_15l_health_and_human_services_--_segment_15.pdf | |
| File Size: | 221 kb |
| File Type: | |
| exec_15_extra_hhs_and_covid_vaccines_--_segment_15.pdf | |
| File Size: | 80 kb |
| File Type: | |